Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
July 21, 2020
The Center for Biosimilars
On July 21, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. They discussed the differences in how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act and the new challenges follow-on manufacturers will face.
Click here to access the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Concurrences New Frontiers of Antitrust Conference 2026
Sponsorship
Antitrust
Stakeholders 26th Annual CYOC Conference
Event
Antitrust
ALFDP 20th Anniversary Annual Conference
Event
Antitrust
GCR Live: Women in Antitrust 2026
Sponsorship
Antitrust
GICLI Annual Meeting 2026
Sponsorship
Antitrust
Informa CompLaw Advanced EU Conference 2026
Sponsorship
Antitrust
Wild Tomorrow 2026 Annual Gala
Sponsorship
Antitrust
NAPABA Annual Convention 2026
Sponsorship
Antitrust
Law.com General Counsel Conference East 2026
Sponsorship
Antitrust
Economist Enterprise's 1st Annual Antitrust Summit US
Sponsorship
Antitrust
